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In patients with cirrhosis, nitric oxide (NO), asymmetric
dimethylarginine (ADMA), and possibly symmetric dimethylar-
ginine (SDMA) have been linked to the severity of the disease.
We investigated whether plasma levels of dimethylarginines and
NO are elevated in patients with hepatorenal syndrome (HRS),
compared with patients with cirrhosis without renal failure (no-
HRS). Plasma levels of NO, ADMA, SDMA, and L-arginine were
measured in 11 patients with HRS, seven patients with no-HRS,
and six healthy volunteers. SDMA concentration in HRS was
higher than in no-HRS and healthy subjects (1.47 6 0.25 vs. 0.38
6 0.06 and 0.29 6 0.04 lM, respectively; P , 0.05). ADMA and
NOx concentrations were higher in HRS and no-HRS patients
than in healthy subjects (ADMA, 1.20 6 0.26, 1.116 0.1, and 0.53
6 0.06 lM, respectively; P , 0.05; NOx, 94 6 9.1, 95.5 6 9.54,
and 37.67 6 4.62 lM, respectively; P , 0.05). In patients with
HRS there was a positive correlation between serum creatinine
and plasma SDMA (r2¼ 0.765, P , 0.001) but not between serum
creatinine and ADMA or NOx. The results suggest that renal
dysfunction is a main determinant of elevated SDMA concen-
tration in HRS. Accumulation of ADMA as a result of impaired
hepatic removal may be the causative factor initiating renal
vasoconstriction and SDMA retention in the kidney. Exp Biol Med
231:70–75, 2006
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Introduction
Hepatorenal syndrome (HRS), a major complication of
end-stage cirrhosis, is characterized by functional renal
failure and severe alterations in the systemic circulation (for
review see Ref. 1). Impairment of kidney function is a
consequence of marked reduction of renal blood flow
probably caused by activation of specific vasoconstrictor
systems including sympathetic nerves, renin–angiotensin,
and arginine-vasopressin to counteract the vasodilatation of
splanchnic circulation (1). Endothelial nitric oxide (NO)
seems to play a decisive role in determining the decrease in
splanchnic vascular resistance observed in decompensated
cirrhosis (2). Asymmetric dimethylarginine (ADMA), a
guanidino-substituted analogue of L-arginine, is synthetized
endogenously and can act as inhibitor of NO synthase (3),
the enzyme responsible for the formation of NO from L-
arginine. Symmetric dimethylarginine (SDMA), a stereo-
isomer of ADMA, has no inhibitory effect on NO synthase
but may interfere with NO synthesis by competing with L-
arginine for transport across cell membrane (3). ADMA is
excreted in part by the kidneys, but the main metabolic
pathway is degradation by the enzyme dimethylarginine
dimethylaminohydrolase (DDAH) to L-citrulline (4). Nij-
veldt et al. (5) hypothesized a causal role for ADMA in the
development of HRS. They proposed that accumulation of
ADMA, probably caused by impaired hepatic removal, may
have detrimental effects on renal function by inhibiting NO
synthesis, thereby interfering with renal blood flow and
glomerular filtration (5). In contrast to ADMA, SDMA is
eliminated by renal clearance and cannot be degraded by
DDAH (4). Recently, Siroen and co-workers (6) have
shown that the human liver takes up substantial amounts of
SDMA from the portal and systemic circulation and
suggested that high plasma levels of SDMA may have
hemodynamic consequences similar to those reported for
ADMA. To date, increased ADMA blood levels have been
documented in patients with end-stage liver disease before
liver transplantation (7) and in alcoholic cirrhosis (8). In
patients with alcoholic cirrhosis, increased ADMA and NO
levels correlate strongly with severity of the disease.
However, plasma levels of SDMA are within normal values
in alcoholic cirrhosis (8).
Plasma levels of dimethylarginines and NO in HRS are
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not known. We hypothesized that the renal failure that
accompanies cirrhosis might trigger changes in plasma
levels of NO and dimethylarginines different from those
observed in human alcoholic cirrhosis with normal renal
function. Accordingly, the aim of the present study was to
evaluate plasma levels of dimethylarginines (ADMA and
SDMA) and NO, measured as plasma nitrite plus nitrate
(NOx concentration), in patients with HRS and in patients
with cirrhosis without renal failure.
Materials and Methods
Eleven patients with HRS (eight men, three women;
mean age 54 6 3 years) were included in the study. Seven
patients had Type 1 HRS and four Type 2 HRS. The HRS
was diagnosed according to the criteria proposed by the
International Ascites Club (9): a low glomerular filtration
rate as assessed by serum creatinine concentration greater
than 1.5 mg/100 ml, proteinuria less than 500 mg/day,
absence of shock, bacterial infection and fluid losses, no
improvement of renal function (as based on serum creatinine
levels) after oral diuretic withdrawal and plasma volume
expansion, and no ultrasonographic evidence of renal disease
or uninary tract obstruction. The diagnosis of cirrhosis was
based on clinical, biochemical, and ultrasonographic find-
ings in all patients. In eight patients, the diagnosis was
confirmed by liver biopsy. All patients had moderate to
severe ascites. The presence of ascites was confirmed by
diagnostic paracentesis. According to the Pugh classification
(10), eight patients belonged to class C, and three patients to
class B, with a Child-Pugh score above 8. The cause of
cirrhosis was alcoholic in six, hepatitis C virus in three, and
hepatitis B virus in two. None of the studied subjects had
heart failure, hypertension, or diabetes mellitus.
The results obtained in the HRS were compared with
those from a group of patients with cirrhosis without renal
failure. This group comprised seven patients (five men, two
women; mean age 59 6 3 years) with alcoholic (4 patients)
or virus-related cirrhosis (three patients). All the patients in
this group had moderate to severe ascites. These patients
belonged to class B–C with a Child-Pugh score above 8 and
had normal renal function. In addition, another group
consisted of six healthy subjects (four men, two women;
mean age 58 6 3 years) with normal laboratory findings.
The study was undertaken with the approval of the local
ethics committee and after obtaining informed consent from
each patient.
Determination of L-Arginine and Dimethylargi-
nines. Plasma concentrations of L-arginine, ADMA, and
SDMA were accomplished by high-performance liquid
chromatography using a modification of a previously
described method (3). In brief, dimethylarginines from 1
ml of plasma were purified with Bond Elut SCX columns
and eluted with 4 ml of methanol containing 30% distilled
water and 2% triethylamine. The eluent was then evaporated
to dryness at 608C, and the dried extract was redissolved in
running buffer. High-pressure liquid chromatography was
carried out on a Shimadzu chromatography system
(Shimadzu Corporation, Kyoto, Japan). Separation of
dimethylarginines was achieved with a 250 3 4.6-mm
(inner diameter), 5-lm Kromasil C18 analytic column using
25 mM phosphoric acid containing 10 mM hexane sulfonic
acid and 1% (v/v) acetonitrile, pH 5.0. The analysis was
carried out at a flow rate of 1.3 ml/min, and the absorbance
monitored at 200 nm. Concentrations of L-arginine, ADMA,
and SDMA in the samples were determined by comparison
with standards. The variability of the method was below
7%, and the detection limit of the assay was 0.1 lM.
Determination of Nitrite Plus Nitrate (NOx). NO
is rapidly converted to nitrite and nitrate in human plasma.
In our study, plasma NOx levels were measured in triplicate
after conversion of nitrate to nitrite by nitrate reductase and
nitrite measured by using the Griess reaction, as described
previously (11). The intra- and interassay coefficients of
variation were 3% and 7%, respectively. Recoveries of both
nitrites and nitrates in our samples were greater than 95%.
Statistical Analysis. Results are expressed as mean
6 SE. Data were analyzed by ANOVA and Fisher’s
multiple comparison tests. The unpaired t test was applied
for comparisons of means of study groups. Statistical
significance was accepted when P values were less than
0.05. Linear regression analyses and correlation coefficients
were calculated according to the least-squares methods. The
statistical analyses were carried out using the Statistical
Package for the Social Sciences (SPSS Inc., Chicago, IL)
version 12 for Windows.
Results
Table 1 shows the main clinical and laboratory data of
healthy subjects, patients with HRS, and cirrhotic patients
without HRS. Both groups of patients were similar with
respect to the severity of liver failure. Moreover, there were
no significant differences between the two groups with
respect to the other baseline variables except for serum
creatinine.
The plasma concentrations of ADMA, SDMA, NOx,
and L-arginine are presented in Figure 1. In the HRS group,
SDMA concentration was about fourfold higher compared
to healthy subjects and patients with cirrhosis with normal
kidney function (1.47 6 0.25 vs. 0.29 6 0.04 and 0.38 6
0.06 lM, respectively; P , 0.05). ADMA concentrations
were higher in both groups of patients when compared to
controls (1.20 6 0.26 in HRS, 1.11 6 0.10 in cirrhosis
without HRS, and 0.53 6 0.06 lM in healthy subjects; P ,
0.05 between patients and controls). No significant differ-
ences in ADMA concentrations were observed between
HRS and cirrhosis with normal renal function (P ¼ 0.33).
NOx concentrations were higher in both groups of
patients than in controls (94.00 6 9.15 lM in HRS, 95.50
6 9.54 lM in cirrhosis with no HRS, and 37.67 6 4.62
lM in healthy subjects; P , 0.05). No significant differ-
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ences were observed between patients with or without HRS
(P¼ 0.49). L-Arginine levels were not significantly different
among the three groups.
In patients with HRS, a significant positive correlation
was observed between SDMA and serum creatinine (r2 ¼
0.765, P , 0.001) but not between ADMA and creatinine
(r2¼ 0.038, P¼ 0.564) (Fig. 2). No correlation was shown
between NOx and creatinine (r
2 ¼ 0.024, P ¼ 0.648).
Table 1. Clinical and Laboratory Findings
Healthy controls Cirrhosis with HRS Cirrhosis without HRS
Number 6 11 7
Men/women 4/2 8/3 5/2
Age (years) 58 6 3 54 6 3 59 6 3
Child-Pugh score — 10.5 6 0.5 10.0 6 0.4
Mean arterial pressure (mm Hg) 85 6 4 76 6 4 80 6 3
Albumin (g/dL) 4.2 6 0.1 2.7 6 0.2* 3.0 6 0.2*
Bilirrubin (mg/dL) 0.6 6 0.1 5.1 6 1* 4.0 6 0.6*
Prothrombin time (%) 93.2 6 0.6 50.7 6 4.1* 54.0 6 4.0*
Serum creatinine (mg/dL) 0.9 6 0.1 2.6 6 0.4*,** 1.1 6 0.1
* P , 0.05 vs. control; ** P , 0.05 vs. cirrhosis without HRS.
Figure 1. Individual plasma concentration of NOx, L-arginine, ADMA, and SDMA in healthy subjects (n¼6), patients with hepatorenal syndrome
(HRS, n¼ 11), and patients with cirrhosis without renal dysfunction (n ¼ 7). Horizontal bars indicate mean 6 SE. *P , 0.05.
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The molar ratios between L-arginine and ADMA and
SDMA concentrations are shown in Figure 3. Although the
ratio between L-arginine and ADMA was significantly lower
in the two groups of patients when compared with healthy
subjects, the L-arginine/SDMA molar ratio was markedly
decreased only in patients with HRS.
Discussion
The main finding of this study is that plasma
concentrations of NOx, ADMA, and SDMA are elevated
in patients with HRS compared with control subjects.
SDMA, but not ADMA, is positively correlated with serum
creatinine in patients with HRS. NOx and ADMA were
increased in all patients compared with healthy subjects. A
recent study in alcoholic cirrhosis has shown that plasma
concentrations of both NOx and ADMA are positively
correlated with the degree of liver failure (8). Because in the
present report the two groups of patients revealed similar
liver impairment, as indicated by the Child-Pugh score, no
differences in NOx and ADMA plasma levels were
observed. The rise in ADMA levels coinciding with an
increase in NOx in cirrhotic patients has been interpreted as
a compensatory mechanism to counterbalance excessive
peripheral vasodilatation in the splanchnic vascular bed in
response to increased synthesis of NO (8).
SDMA plasma levels do not correlate with the clinical
score and remain within normal values in alcoholic cirrhosis
with normal renal function (8) and in patients with end-stage
liver failure before liver transplantation (7). This strongly
suggests that the high levels of SDMA observed in our
group of patients with HRS are caused by impairment of
renal function. As a consequence, SDMA was not correlated
with NOx, but it was significantly correlated with serum
creatinine. A positive correlation between plasma SDMA
concentrations and serum creatinine has been previously
demonstrated in patients with chronic renal failure from
primary renal disease in the absence of liver dysfunction (3,
13, 15). After kidney transplantation, the concentrations of
SDMA returned to baseline values (15). On the other hand,
we found no correlation between plasma levels of ADMA
and serum creatinine, which indicates that the increase in
plasma ADMA in patients with HRS was not caused by a
decrease in renal clearance of ADMA.
The liver plays an important role in the metabolism of
ADMA by taking up large amounts from the systemic
circulation (5). The enzyme dimethylarginine dimethylami-
nohydrolase (DDAH) is highly expressed in the liver (12)
and removes ADMA by metabolizing it to L-citrulline and
dimethylamine (4). A decrease in the activity of DDAH in
the liver would lead to an increase in ADMA and a decrease
in the local production of NO. A decrease in NO production
by sinusoidal endothelial cells in the cirrhotic liver is an
important factor in the development and maintenance of
portal hypertension (2). In contrast to ADMA, SDMA is
eliminated by renal clearance and cannot be degraded by
DDAH (4). The significance of high plasma levels of
SDMA in HRS is uncertain because there is no evidence
that it may inhibit NO synthase (3). However, SDMA at
high concentrations may interfere with NO production by
blocking cellular L-arginine uptake (3, 14). Indeed, in
primary chronic renal failure, the high plasma levels of
ADMA and SDMA seem to be responsible for the increase
in systemic arterial pressure (15). Therefore, SDMA, and
not only ADMA, is likely to be one factor responsible for
the increased intrarenal vascular resistance observed in
HRS.
The pathogenesis of renal vasoconstriction in cirrhosis
is multifactorial (1). Several lines of evidence suggest that
Figure 2. Correlation analyses between serum creatinine SDMA and ADMA in patients with hepatorenal syndrome.
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splanchnic arterial vasodilatation caused by an increased
synthesis of NO plays a main role in the initiation of
reduced renal perfusion. Intravenous administration of NO
synthase inhibitors to cirrhotic patients increases renal blood
flow and glomerular filtration rate, probably through an
increase in renal perfusion caused by an increment in
systemic arterial pressure in these patients (16). These
findings led to the suggestion that NO synthase inhibitors
might be useful in the treatment of ascites in cirrhosis (17).
However, experiments in cirrhotic rats raise the possibility
that NO blockade may have deleterious effects by increas-
ing intrahepatic vascular resistance (18). Moreover, it is
possible that the plasma concentrations of ADMA achieved
in cirrhosis could be biologically effective in renal vessels.
With regard to this, it has been proposed that increased
ADMA in hepatic dysfunction plays an important role in the
development of renal failure in patients with cirrhosis (5).
Indeed, ADMA elicits contractile effects on human renal
(19) and cerebral (20) arteries. In addition, NO synthase
inhibitors enhance vascular contractile responses to adre-
nergic agonists and sympathetic stimulation of human
arteries (21, 22). Thus, elevated ADMA levels could
promote renal vasoconstriction by blocking NO synthesis
in the endothelium of renal vessels as well as potentiating
the effects of perivascular sympathetic nerves. This would
lead to impairment of renal function and SDMA retention.
In conclusion, the present study demonstrated an
elevation of NOx, ADMA, and SDMA in patients with
HRS. Only SDMA correlates positively with serum
creatinine. These findings have two important implications.
First, they suggest that SDMA may be a marker of renal
dysfunction in cirrhosis. Second, accumulation of ADMA,
caused by impaired hepatic removal, may be a factor
determining not only the elevated intrahepatic vascular
resistance but also the renal vasoconstriction and SDMA
retention by the kidney.
1. Gines P, Guevara M, Arroyo V, Rodes J. Hepatorenal syndrome.
Lancet 362:1819–1827, 2003.
2. Martin PY, Gines P, Schrier RW. Nitric oxide as a mediator of
hemodynamic abnormalities and sodium and water retention in
cirrhosis. N Engl J Med 339:533–541, 1998.
3. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of
an endogenous inhibitor of nitric oxide synthesis in chronic renal
failure. Lancet 339:572–575, 1992.
4. Ogawa T, Kimoto M, Sasaoka K. Purification and properties of a new
enzyme, NG, NG-dimethylarginine dimethylaminohydrolase, from rat
kidney. J Biol Chem 264:10205–10209, 1989.
5. Nijveldt RJ, Teerlink T, Van Leeuwen PAM. The asymmetrical
dimethylarginine (ADMA)—multiple organ failure hypothesis. Clin
Nutr 22(1):99–104, 2003.
6. Siroen MP, van dSJ, Teerlink T, van Schaik C, Nijveldt RJ, van
Leeuwen PA. The human liver clears both asymmetric and symmetric
dimethylarginine. Hepatology 41:559–565, 2005.
Figure 3. Plasma L-arginine/ADMA molar ratio and L-arginine/SDMA molar ratio in healthy subjects (n¼6), patients with hepatorenal syndrome
(HRS, n¼ 11) and patients with cirrhosis with normal renal function (n ¼ 7). Data are mean 6 SE. *P , 0.05.
74 LLUCH ET AL
7. Tsikas D, Rode I, Becker T, Nashan B, Klempnauer J, Frolich JC.
Elevated plasma and urine levels of ADMA and 15(S)-8-iso-PGF2alpha
in end-stage liver disease. Hepatology 38:1063–1064, 2003.
8. Lluch P, Torondel B, Medina P, Segarra G, Del Olmo JA, Serra MA,
Rodrigo JM. Plasma concentrations of nitric oxide and asymmetric
dimethylarginine in human alcoholic cirrhosis. J Hepatol 41:55–59,
2004.
9. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G,
Reynolds TB, Ring-Larsen H, Scholmerich J. Definition and diagnostic
criteria of refractory ascites and hepatorenal syndrome in cirrhosis.
International Ascites Club. Hepatology 23:164–176, 1996.
10. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R.
Transection of the oesophagus for bleeding oesophageal varices. Br J
Surg 60:646–649, 1973.
11. Moshage H, Kok B, Huizenga JR, Jansen PL. Nitrite and nitrate
determinations in plasma: a critical evaluation. Clin Chem 41:892–896,
1995.
12. Kimoto M, Tsuji H, Ogawa T, Sasaoka K. Detection of NG, NG–
dimethylarginine dimethylaminohydrolase in the nitric oxide–generat-
ing systems of rats using monoclonal antibody. Arch Biochem Biophys
300:657–662, 1993.
13. Kielstein JT, Boger RH, Bode-Boger SM, Frolich JC, Haller H, Ritz E,
Fliser D. Marked increase of asymmetric dimethylarginine in patients
with incipient primary chronic renal disease. J Am Soc Nephrol 13:
170–176, 2002.
14. Closs EI, Basha FZ, Habermeier A, Forstermann U. Interference of L-
arginine analogues with L-arginine transport mediated by the yþ carrier
hCAT–2B. Nitric Oxide 1:65–73, 1997.
15. Fleck C, Janz A, Schweitzer F, Karge E, Schwertfeger M, Stein G.
Serum concentrations of asymmetric (ADMA) and symmetric (SDMA)
dimethylarginine in renal failure patients. Kidney Int Suppl 78:S14–
S18, 2001.
16. La Villa G, Barletta G, Pantaleo P, Del Bene R, Vizzutti F, Vecchiarino
S, Masini E, Perfetto F, Tarquini R, Gentilini P, Laffi G.
Hemodynamic, renal, and endocrine effects of acute inhibition of
nitric oxide synthase in compensated cirrhosis. Hepatology 34:19–27,
2001.
17. Martin PY, Ohara M, Gines P, Xu DL, St John J, Niederberger M,
Schrier RW. Nitric oxide synthase (NOS) inhibition for one week
improves renal sodium and water excretion in cirrhotic rats with ascites.
J Clin Invest 101:235–242, 1998.
18. Gupta TK, Toruner M, Chung MK, Groszmann RJ. Endothelial
dysfunction and decreased production of nitric oxide in the intrahepatic
microcirculation of cirrhotic rats. Hepatology 28:926–931, 1998.
19. Segarra G, Medina P, Vila JM, Chuan P, Domenech C, Torondel B,
Lluch S. Inhibition of nitric oxide activity by arginine analogs in human
renal arteries. Am J Hypertens 14:1142–1148, 2001.
20. Segarra G, Medina P, Ballester R, Lluch P, Aldasoro M, Vila JM, Lluch
S. Effects of some guanidino compounds on human cerebral arteries.
Stroke 30:2206–2211, 1999.
21. Torondel B, Vila JM, Segarra G, Lluch P, Medina P, Martinez-Leon J,
Ortega J, Lluch S. Endothelium-dependent responses in human isolated
thyroid arteries from donors. J Endocrinol 181:379–384, 2004.
22. Aldasoro M, Martı´nez C, Vila JM, Flor B, Lluch S. Endothelium-
dependent component in the contractile responses of human omental
arteries to adrenergic stimulation. Eur J Pharmacol 250:103–107, 1993.
DIMETHYLARGININE IN HEPATORENAL SYNDROME 75
